Call 21: Development of therapeutics and diagnostics combatting coronavirus infections

Call 21: H2020-JTI-IMI2-2020-21-SINGLE-STAGE 

"DEVELOPMENT OF THERAPEUTICS AND DIAGNOSTICS COMBATTING CORONAVIRUS INFECTIONS"

Open :                                          3 March 2020
Submission Deadline :                31 March 2020
Financement :                             From EFPIA companies and IMI2 Associated Partners: to be defined                                                                                               based upon selected proposals
                                                     From the IMI2 JU: 45 M€

SCOPE: 

Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the following objectives:

• development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak;
• development of therapeutics to address the current and/or future coronavirus outbreaks;
• development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
• development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

Preventive vaccines are specifically excluded from the scope of the Call.

MORE INFORMATION ABOUT THE CALL AND PROCEDURES ARE AVAILABLE HERE.

More information here about the IMI held webinar on IMI2 – Call 21 on the novel coronavirus on Wednesday 4 March. The webinar featured presentations of the topic as well as IMI’s rules and procedures for this fast-track, single stage Call for proposals.